Table 4 Univariate and multivariate analysis of factors associated with clinical cure in 181 patients with CRO infections
From: Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
Characteristic | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Odds ratio (95% confidence interval) | P-value | Odds ratio (95% confidence interval) | P-value | |
Age (years) | 1.006 (0.987, 1.026) | 0.547 | ||
Male | 1.111 (0.563, 2.193) | 0.761 | ||
APACHE II score | 0.944 (0.897, 0.993) | 0.027 | 0.880 (0.811 0.955) | 0.002 |
Comorbidities | ||||
Chronic heart failure | 0.587 (0.322, 1.067) | 0.081 | ||
Diabetes mellitus | 0.975 (0.542, 1.755) | 0.933 | ||
COPD | 0.761 (0.390, 1.483) | 0.422 | ||
Chronic kidney disease | 1.069 (0.574, 1.990) | 0.833 | ||
Immunosuppressive status | 1.017 (0.550, 1.879) | 0.957 | ||
Infection types | ||||
Pneumonia | 0.595 (0.328, 1.078) | 0.087 | ||
Bloodstream infection | 0.499 (0.235, 1.061) | 0.071 | ||
Multiple site infections | 0.530 (0.248, 1.131) | 0.101 | ||
Responsible pathogens | ||||
K.P | 0.893 (0.498, 1.603) | 0.705 | ||
P.A | 0.508 (0.258, 1.000) | 0.050 | ||
E. coli | 2.395 (0.797, 7.197) | 0.120 | ||
A.B | 0.236 (0.049, 1.143) | 0.073 | ||
Multiple bacterial infections | 0.393 (0.144, 1.073) | 0.068 | ||
Polymyxin B dose | 2.367 (1.403, 3.991) | 0.001 | 1.376 (0.558, 3.394) | 0.488 |
Initial treatment | 2.169 (1.177, 3.995) | 0.013 | 1.643 (0.662, 4.077) | 0.284 |
Duration of polymyxin B treatment(days) | 1.168 (1.103, 1.236) | ≤ 0.001 | 1.157 (1.077, 1.243) | ≤ 0.001 |
Antibiotic combination | 3.987 (1.074, 14.811) | 0.039 | 3.853 (0.627, 23.668) | 0.145 |
Microbiological eradication | 26.541 (11.510, 61.202) | ≤ 0.001 | 21.345 (8.007, 56.901) | ≤ 0.001 |